custirsen + docetaxel + prednisone

This is a **combination regimen** comprising **custirsen**, **docetaxel**, and **prednisone**. - **Custirsen** is a second-generation antisense oligonucleotide targeting the mRNA of clusterin, a chaperone protein associated with treatment resistance and upregulated by apoptotic stress such as chemotherapy. By inhibiting clusterin production, custirsen is intended to increase cancer cell sensitivity to standard therapies. - **Docetaxel** is a taxane-class cytotoxic chemotherapy agent that promotes microtubule assembly and inhibits microtubule depolymerization, disrupting mitosis and blocking cell division. - **Prednisone** is a synthetic glucocorticoid used for its anti-inflammatory and immunosuppressive effects and to mitigate chemotherapy side effects such as hypersensitivity reactions and fluid retention. This regimen was evaluated primarily as first-line therapy for **metastatic castration-resistant prostate cancer** (mCRPC), investigating whether the addition of custirsen to standard docetaxel and prednisone would improve overall survival. Phase 3 results showed that while the combination was reasonably well tolerated, it did not significantly prolong overall survival compared to docetaxel and prednisone alone[1][2][3].